ADC Bio’s $1.5m investment to boost antibody-drug conjugate manufacturing

By Flora Southey

- Last updated on GMT

(Image: Getty/media point inc)
(Image: Getty/media point inc)
ADC Bio has announced receipt of a £1.14m investment it says will help reduce antibody-drug conjugate manufacturing time and costs.

London-based investment managers Downing LLP has financed the project – which is equivalent to $1.5m – to advance ADC Biotechnology’s (ADC Bio) bioconjugation method, as well as help the contract manufacturing organisation (CMO) secure more US contracts.

ADC Bio’s method undertakes bioconjugation for antibody-drug conjugates (ADCs) after the monoclonal antibody (mAb) and cytotoxic have been made, and purifies both elements at the same time.  

The method employs the firm’s Lock-Release​ technology platform to separate the antibodies from each other through binding to a solid phase bead, and therefore is not reliant on Protein A capture resin.

Compared to other conventional techniques​, ADC Bio’s bioconjugation method “involves use of a solid-phase conjugation approach that is advantaged by its ability to avoid aggregation,” ​said CEO Charlie Johnson.

The Wales, UK-based company makes ADCs efficiently without having to go through production and purification of an isolated antibody intermediate in a precursor step, he added.

According to Johnson, the method will help advance the manufacture of new therapies.

“The manufacture of ADCs for First in Man clinical trials is where lead times are critical," ​he added. “It will cut down significantly the lead-time for supply of ADCs into clinical trials and will lower the cost of manufacturing.”

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more